Xenon(XENE) - 2024 Q2 - Quarterly Results

Exhibit 99.1 X XENON Xenon Reports Q2 2024 Financial Results and Business Update – Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 – MDD program on track with Phase 3 study expected to initiate in H2 2024 – Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia, August 8, 2024 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurosciencefocused biopharmaceutical com ...